Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Prevalence of Claudin 18.2 Expression in Patient Subgroups and Co-expression of Claudin 18.2 with the KRAS G12D Mutation in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma in Germany.

Peter J. Wild, Marco Gross-Langenhoff, Clare McCabe, Julia Bein, Anna Hof, Martin Glasstetter, Georgia Gourgioti, Lawrence Chang, Anouk van Oosten, Holly Dasghaib, Martina Jänicke, Karin Potthoff

Oncol Res Treat 2025;48 (suppl 2):195

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2025
Neoadjuvant nivolumab plus platinum-based chemotherapy in patients with non-metastatic resectable NSCLC: Interim data from the non-interventional study NENI.

Eichhorn, M; Reiser, M; Meyer zum Büschenfelde, C; Faehling, M; Hammerschmidt, S; von der Heyde, E; Hoffknecht, P; Möller, M; Meyn, P; Kokowski, K; Metzenmacher, M; Brueckl, W; Buettner, R; Griesinger, F; Bluhmki, T; Dauber, K; Waldenberger, D; Hillejan, L.

Zentralblatt für Chirurgie 2025; 150(S01): 88 – 89. DOI: 10.1055/s-0045-1809760

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGT / Journal: Zentralblatt für Chirurgie
NENI
2025
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.

Goebell PJ, Bögemann M, Nusch A, Grünwald V, Müller L, von der Heyde E, Martens UM, Lennartz C, Koska M, Potthoff K, Kaiser-Osterhues A, Grüllich C, Staehler M, Jänicke M, Marschner D; CARAT Registry Group.

Int J Cancer. 2025 Oct 29. doi: 10.1002/ijc.70211. Epub ahead of print.

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: International Journal of Cancer
CARAT
2025
Prospective validation of the metastatic colorectal cancer score (mCCS) in patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Potthoff K, Uhlig J, Jacobasch L, Müller L, Reiser M, Schuch A, Serrer L, de Buhr RK, Siebenbach HU, Göhler T, Schröder J, Semsek D, Köhler A, Stübs P, Marschner N.

Int J Cancer. 2025; 1-12. doi:10.1002/ijc.70139

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: International Journal of Cancer
VALIDATE
2025
Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer.

Potthoff K, Marschner N, Müller L, Sahm S, Lerchenmüller C, Depenbusch R, Boller E, Niemeier B, Zirrgiebel U, Tesch H.

J Gastrointest Cancer. 2025 Jun 27;56(1):141. doi: 10.1007/s12029-025-01260-6.

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Journal of Gastrointestinal Cancer
ERBIMOX
2025
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.

Welslau M, Potthoff K, Zaiss M, Müller L, Brucker C, Salat C, Untch M, Meiler J, Lüftner D, Welt A, Dörfel S, Hagen V, Stein A, Liersch R, Kuhn T, Siebenbach HU, Bing G, Vannier C, Marschner N, Gratzke K.

Oncol Res Treat. 2025;48(1-2):14-25. doi: 10.1159/000542459. Epub 2024 Nov 15. PMID: 39551040; PMCID: PMC11809519.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Oncology Research and Treatment
INGE-B
2025
Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry.

Potthoff K, Bläker H, Dechow T, Binninger A, Ringwald K, de Buhr R, von der Heyde E, Zahn M.-O., Nusch A, Dörfel S, Schulz H, Haffner I, Höhn A.K., Monecke A, Lorenzen S, Reinacher-Schick A, Jänicke M, Lordick F.

ESMO Real World Data Digit Oncol. 2025 June; Volume 8: 100144. doi:10.1016/j.esmorw.2025.100144. Epub 2025 Apr 29.

Abstract

Indikation: Gastric Cancer, Magenkarzinom / Veranstaltung: - / Journal: ESMO Real World Data and Digital Oncology
SAPHIR
2025
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K, Kaltenecker G, Ringwald K, Gratzke K, Dille S, Kruggel L, Jänicke M, Schulz H, Hagen V, Fricker R, Stickeler E, Harbeck N, Wöckel A, Decker T.

Int J Cancer. 2025 May 1;156(9):1770-1782. doi: 10.1002/ijc.35296. Epub 2024 Dec 20. PMID: 39707595; PMCID: PMC11887017.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: International Journal of Cancer
OPAL
2025
Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting.

Decker T, Zaiss M, Klein D, Hahn A, Hagen V, La Rosée P, Liersch R, Wolff T, Niemeier B, Hillebrand LE, Lennartz C, Chiabudini M, Bengsch F, Indorf M, Marschner N.

Breast Care (Basel). 2024 Feb;19(1):49-61. doi: 10.1159/000535135. Epub 2023 Dec 20.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Care
RIBBIT
2024
Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study.

Marschner N, Haug N, Hegewisch-Becker S, Reiser M, Dörfel S, Lerchenmüller C, Linde H, Wolf T, Hof A, Kaiser-Osterhues A, Potthoff K, Jänicke M; TPK‐Group (Tumour Registry Pancreatic Cancer).

Int J Cancer. 2024 Nov 1;155(9):1629-1640. doi: 10.1002/ijc.35071. Epub 2024 Jul 2.

Abstract

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: - / Journal: International Journal of Cancer
TPK
2024